Wednesday, March 2

3:00 – 4:00 PM EST

Re-Thinking Cancer Survivorship

**Barbara McAneny, MD, MACP, FASCO**, Chief Executive Officer, New Mexico Cancer Center, Oncology Hematology Consultants

@BarbaraMcAneny

**Kimberly Peairs, MD**, Vice Chair for Ambulatory Operations, Department of Medicine; Associate Professor of Medicine, *The Johns Hopkins Hospital, The Sidney Kimmel Comprehensive Cancer Center*

**Lauren Wallner, PhD, MPH**, Assistant Professor, Department of Medicine, Division of General Medicine and Assistant Professor, Department of Epidemiology; Adjunct Investigator *University of Michigan*

@LaurenWallner

Once a comprehensive cancer survivorship plan is developed by oncology, it is widely accepted that clinical management of the survivorship plan is routinely assumed by the patient's primary care physician (PCP). But is that the best—and most cost effective—model to deliver cancer survivorship care? And does this model take into account patient perspectives or preferences? Learn what research has found, including the features of a well-designed survivorship communication process. Then hear different models for delivering comprehensive cancer survivorship care, from embedding primary care in oncology to the reverse—embedding oncology in primary care.

4:00 – 5:30 PM EST

What’s New with Big Data?

**Jennifer Urban**, Partner, *Foley & Lardner*

**James Hamrick, MD, MPH**, Vice President, Clinical Oncology *Flatiron Health*

@HJamesHamrick

**Nick Accomando**, Compliance and Privacy Officer, *Flatiron Health*

**Emily Wampfler**, Senior Director of Product Management, *Mayo Clinic*
Thursday, March 3

7:00 – 8:00 AM EST

Networking Breakfast with Table Talks

Technology Platforms: What Technologies Are Moving the Needle in Care Delivery?
Gitesh Patel, Director Global Business Development, Comprehensive Blood & Cancer Center; CEO, SPAC Int’l

Value-Based Care: Where We’ve Been and Where We’re Headed
Michael Kolodziej, MD, VP & Chief Innovation Officer, ADVI

Consolidation & Competition: Where Do I Best Fit Within My Consolidating Market? Do I Sell or Do I Buy?
Barbara McAneny, MD, President, New Mexico Oncology Hematology Consultants & Past-President, American Medical Association

Revenue Cycle & Reimbursement: Challenges, Frustrations and How to Overcome Them
Ron DiGiaimo, Chairman, Revenue Cycle Coding Strategies

Pharmacy & Infusion Operations: Challenges, Frustrations and How to Overcome Them
Deidre Saulet, PhD, Partner, Advisory Board Company

Precision Medicine: Challenges, Frustrations and How to Get Paid for It
Ira Klein, MD, VP Medical Affairs & Payer Relations, Tempus Labs

Patient Support: Navigation, Financial Toxicity, Patent Reported Outcomes (PROs)
Amila Patel, PhD, Navigating Cancer

Workforce Issues: Staff Burnout, Employee Recruiting & Retention and Re-Thinking the Workplace
Kelley Simpson, Leader, Oncology Solutions Practice, Director, The Chartis Group

8:00 – 9:00 AM EST

Welcome and Keynote Address: (Over)-Paying for Cancer Care
Cary Gross, MD, Professor of Medicine and Director of the Cancer Outcomes Public Policy and Effectiveness Research (COPPER) Center, Yale School of Medicine; co-author, A New Deal for Cancer Care: Lessons From a 50 Year War

@cpgYALE
Learn how the rise in cancer costs is attributable to a “cancer cost trifecta”—more cancers are being diagnosed, there is a higher utilization of cancer-related care, and there are now more expensive testing and treatment options available. Hear how a range of policy initiatives and reforms could help realign the interests of the scientists, providers, policy makers, and industry in order to prioritize patients and the public and reduce cancer costs. These include ramping up tobacco control efforts, supporting evidence-based prevention strategies (e.g., cervical cancer vaccination and colorectal cancer screening), and using payment reform to encourage high-value care. To reduce prescription drug spending, Gross supports the following measures: (1) expediting generic and biosimilar agents; (2) decoupling patient deductibles and co-pays from the cost of cancer care; (3) basing prices for new and existing therapies on their clinical benefits (“value-based pricing”); and (4) decoupling payer reimbursement from the FDA approval process.

9:00 – 10:00 AM EST

**Industry Reconfiguration: Who’s the Boss?**

**Mike Kolodziej, MD**, Vice President and Chief Innovation Officer, *ADVI Health, LLC* (Moderator)

**Lee Blansett**, Principal, *Proximity Health*

**Harlan Levine, MD**, President, Strategy and Business Ventures, *City of Hope National Medical Center*

@drharlanlevine

**Paul Martino**, Co-Founder and Chief Growth Officer, *VillageMD*

@paul_villagemd

**Brian Wydra**, Senior Vice President, Oncology & Infusion, *OptumCare*

Hear an overview of industry reconfiguration and consolidation trends and its impact on oncology. Learn the value propositions of three different business models and how each improves cancer care services in terms of access, quality, outcomes, and cost. Then listen to a panel discussion of how these other models may impact the delivery of cancer care going forward, followed by an interactive audience Q&A.

10:00 – 10:30 AM EST

**Networking Break**

10:30 – 11:00 AM EST

**Industry Consolidation: The Nuts & Bolts**

**Adria Warren**, Partner, *Foley & Lardner*

**Tynan Kugler**, CVA, Principal, *PYA*

@TOKugler

**Phil Watts**, General Counsel, *OneOncology*

Oncology transactions are often complex and require keen attention to numerous regulatory, compliance, operational, and financial
issues. From deal structure to due diligence, this session will highlight key consolidation considerations, including compliance with applicable laws and identification of risk area as well as offer practical guidance to navigating the factors critical to a successful partnership.

11:05 AM – 12:05 PM EST

**How to Evaluate the Impact of Cancer Programs and Clinical Services**

**Rebekkah Schear, MIA,** Associate Director, Patient Experience; Co-Founder, Imagination Lab for Clinical Innovation

[[@BekkahScheck]](https://twitter.com/BekkahScheck)

**Robin Richardson, MA,** Assistant Director of Care Delivery Transformation & Community Engagement; Co-Founder, Imagination Lab for Clinical Innovation

*The University of Texas Dell Medical School, LIVESTRONG Cancer Institutes*

[[@RNinAustin]](https://twitter.com/RNRinAustin)

How do I know if my cancer program is improving patient outcomes and quality of life? How can we assess if new models of care are working? Join us for this session and learn about the robust impact, quality, and evaluation strategy Livestrong Cancer Institutes developed to measure its new model of person-centered cancer care. During this interactive discussion, presenters share the nuts and bolts of their evaluation, including a PRO strategy for measuring patient experiences (PREMs); how to measure clinical outcomes, access to care, and care coordination; and how to measure cancer care provider experience and attitudes. Then do a deep dive into how their team built and deployed a massive chart abstraction to assess utilization of supportive care services by patients; development and deployment of a patient experience survey; how to design a study for qualitative data collection from patients; and how to develop and field a provider experience survey to evaluate whether the provider team is happy, if their work is meaningful, and measure their level of resilience.

12:05 – 1:00 PM EST

**Networking Lunch with Table Talks**

**Digital Health/AI in Cancer Care**

**David Penberthy, MD, MBA,** Medical Director of Radiation Oncology, *Bon Secours, Southside Regional Medical Center Cancer Center*

**Anne Marie Rainey, MSN, RN, CHC,** Director of Quality and Value-based Care, *Clearview Cancer Institute*

**Precision Medicine & Targeted Therapies**

**Jennie Crews, MD, MMM, FACP,** Medical Director, SCCA Network & Community Sites, *Seattle Cancer Care Alliance*
Oncology Practice Transformation
Doug Flora, MD, LSSBB, Executive Medical Director, Oncology, St. Elizabeth Cancer Center

Financial Advocacy & Revenue Cycle
Lori Schneider, Operations Manager, Green Bay Oncology
Angie Santiago, CRCS, Manager, Oncology Financial Advocacy, Sidney Kimmel Cancer Center at the Thomas Jefferson University Health System
Rifeta Kajdic-Hodzic, Oncology Program Manager, St. Luke’s Cancer Institute
Francinna Scott-Jones, CPAR, ROCC, Financial Coordinator, Northside Hospital Cancer Institute

Comprehensive Cancer Care Delivery
Krista Nelson, MSW, LCSW, OSW-C, FAOSW, Senior Oncology Social Worker, Program Manager, Providence Health & Services
Al Benson, MD, FACP, FASCO, Professor of Medicine, Robert H. Lurie Comprehensive Cancer Center at Northwestern Medicine

EDI in Cancer Care Delivery
Facilitator TBA

1:00 – 2:10 PM EST

Industry Showcase: Products and Services that Improve/Enhance Clinical Decision Making or Patient Support

Elsevier/Clinical Path
Ed Rodgers, Network Development Director, Clinical Pathways

Elsevier's ClinicalPath presents evidence-based oncology pathways embedded in the clinical workflow to empower high-quality, personalized treatment decisions for your cancer patients. Recognized as ‘Best Computerized Decision Support Solution’ by the MedTech Breakthrough Awards for three consecutive years, ClinicalPath also delivers clinical trial support before the standard of care to help you operate a more efficient cancer research program.

GE Healthcare
Peter Webner, General Manager, Breast Oncology

Metastatic breast lesions may have heterogeneous biomarkers – believed to contribute to low treatment response rates. Treatment decisions are based on incomplete and imperfect information typically from single location biopsies. Until now, there was no available diagnostic tool to measure whole body tumor ER expression in patients with metastatic lesions. Cerianna (F18-Fluoroestradiol) is a diagnostic radioactive agent indicated for use with positron emission tomography (PET) imaging for the detection of estrogen receptor (ER)
positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer

**Flatiron Health (Virtual Presentation)**
Shawn Huda, Director of Product
Rebecca Maniago PharmD, Associate Director

Flatiron Assist™ is a leading clinical decision support tool for oncologists, helping them seamlessly deliver quality care, reduce administrative burdens, and leverage meaningful data to strategically enhance and grow their practice.

**Navigating Cancer**
Amila Patel, PharmD, Chief Clinical Officer

With the wind-down of the OCM program, Navigating Cancer’s Dr. Patel explores the value and potential uses of patient-reported outcome measures (PROs) for new revenue-generating opportunities for providers.

**Cardinal Health**
Tanya Park, Director Innovation Solutions

Features Decision Path, by Cardinal Health Fuse, a platform that empowers oncology practices to make optimal treatment decisions with the right information, at the right time, with a critical view that informs patient care decisions on the spot. Navigate and compare regimens by clinical equivalency and cost, at the point of care, gaining the ability to better manage costs and patient financial toxicity.

**Blueprint Medicines**
Ruthvik Malladi, PharmD, Associate Director Precision Medicine

Review of biomarker and diagnostic guidelines for systemic mastocytosis and considerations for implementation into practice precision medicine workflows.

**Benefits of an Early Mobility Program for Hospitalized Patients with Cancer**

**Mark Liu,** Director, Strategic Initiatives, Oncology Service Line, *Mount Sinai Health System & Tisch Cancer Institute*

This inpatient oncology unit used Activity Measure for Post-Acute Care scores to quantify mobility and then develop team-based, multidisciplinary plans of care in collaboration with physical therapy, nursing, and a mobility aide—a medical assistant with rehabilitation training. Patients were mobilized twice per day, seven days per week.
Staff evaluated the effects of the mobility aide program on quality of care and healthcare utilization and observed significant improvement in both. Outcomes across nearly 1,000 patients include: a 6% reduction in excess days; a reduction of readmission rates from 25% to 19%; three-quarters of patients (76%) maintained or improved their mobility score; and improved patient satisfaction—patient willingness to recommend the hospital increased from 63% to 91%.

2:45 – 3:15 PM EST

Improving Shared Decision-Making Across a Multi-Site Cancer Program

Candice Roth, MSN, RN, CENP, Assistant Vice President, Central Region Operations, Nursing, Quality, Outreach, & Disparities
Melynda Ozan, Consumer Health Librarian; Atrium Health, Levine Cancer Institute

Levine Cancer Institute successfully developed tools and methods to encourage shared decision-making across its network of more than 25 regional sites. Learn how this cancer institute built a standardized treatment platform (Electronically Accessible Pathways, or EAPathways), so all clinicians are using the same evidence-based guidelines, treatment updates, and clinical trials. This ensures that patients across more than 25 clinic locations receive the most consistent, high-quality care possible. Then, in 2017, Levine Cancer Institute hired a consumer health librarian to create a digital library of patient education handouts, including links to approved cancer information websites, which are available to all clinicians and staff through a Microsoft SharePoint site. This health librarian reviews all patient-facing information—including marketing brochures, new visitor policies, and patient education—to ensure materials are written at an appropriate reading level. The health librarian also sits on the Patient and Family Advisory Council, which is often involved in the development of patient resources and chairs the Oncology Patient Education Committee. To further improve shared decision making, Levine Cancer Institute uses a care alignment tool (CAT) to document clinician-patient discussions about goals of care in the patient’s chart for use in advanced care planning. The CAT includes questions that help identify patients' fears or concerns for the future, important goals, and preferences related to using sustaining measures at the end of life.

3:15 – 3:45 PM EST

Networking Break

3:45 – 4:45 PM EST

Prior Authorization: How the Sausage is Made

Mark Sobczak, MD, FACR, Medical Director, Radiation Oncology, Fox Chase Cancer Center
A moderated panel discussion about how current prior authorization processes impact cancer care delivery. Hear four stakeholder perspectives, starting with the emotional effect that prior authorizations—and associated treatment denials and delays—have on patients. Next, learn how burdensome prior authorization requirements are impacting providers, increasing workload and interfering in treatment decisions. Listen to the payer perspective and what is driving the increase in prior authorizations. Finally, learn the role that pathway intermediaries can play in streamlining—or even eliminating—prior authorizations.

**4:50 – 5:50 PM EST**

**Industry Showcase: Products and Services that Improve/Enhance Administrative or Operational Functions**

**Annexus Health**  
Laurie Travasano, Senior Director, Provider Solutions  
AssistPoint. A single enterprise workflow platform that helps provider organizations navigate and manage the patient access journey.

**McKesson**  
Mark Alwardt, Vice President, Medically Integrated Dispensing  
Featuring McKesson technologies and best practices to optimize prescription access for patients and practices, lowers practice costs through maximization and collaborates with PBMs to enhance the role of community oncology.

**LeanTaaS**  
Joe Versino, Director of Sales  
iQueue for Infusion Centers. An advanced technology platform that enables providers to transform infusion center operations through optimized appointments and predictive analytics.

**Chartis Group**  
Melissa McCain, Director, Consumer Access Practice  
Kelley Simpson, Leader, Oncology Solutions Practice
Presenting oncology service line access and care team transformation strategies, drawn from lessons learned working alongside top organizations across the country.

**Tempus Labs**
Amy Gordon Franzen, Vice President, GM of Clinical Trial Solutions

Presenting our TIME Trial Program: A large and growing just-in-time enabled network of Community Hospitals and Biomarker Targeted clinical trials, supported by proprietary, AI-assisted trial matching software

**Friday, March 4**

**6:00 – 8:00 PM EST**

**ACCC Dine Around Event**

**7:00 – 8:00 AM EST**

**Networking Breakfast with Table Talks**

**Technology Platforms: What Technologies Are Moving the Needle in Care Delivery?**
Gitesh Patel, Director Global Business Development, Comprehensive Blood & Cancer Center; CEO, SPAC Int’l

**Value-Based Care: Where We've Been and Where We’re Headed**
Barbara McAneny, MD, President, New Mexico Oncology Hematology Consultants; Past-President, American Medical Association

**Consolidation & Competition: Where Do I Best Fit Within My Consolidating Market? Do I Sell or Do I Buy?**
Adria Warren, Partner, Foley & Lardner

**Revenue Cycle & Reimbursement: Challenges, Frustrations and How to Overcome Them**
Ron DiGiaimo, Chairman, Revenue Cycle Coding Strategies

**Pharmacy & Infusion Operations: Challenges, Frustrations and How to Overcome Them**
Deidre Saulet, PhD, Partner, Advisory Board Company

**Precision Medicine: Challenges, Frustrations and How to Get Paid for It**
Ira Klein, MD, VP Medical Affairs & Payer Relations, Tempus Labs

John Hennessy, SVP, Strategist, Valuate Health Consultancy

**Workforce Issues: Staff Burnout, Employee Recruiting &**
Retention and Re-Thinking the Workplace
Kelley Simpson, Leader, Oncology Solutions Practice, Director, The Chartis Group

7:45 – 8:30 AM EST
AACC House of Delegates Meeting

8:30 – 9:15 AM EST
Keynote: Deconstructing the Value Equation

Harlan Levine, MD, President, Strategy and Business Ventures, City of Hope National Medical Center
@drharlanlevine

Cancer care is a complex—and often controversial—topic, with multiple stakeholders that view “value” through many different lenses. Hear what value in cancer care means to patients and their caregivers and how this meaning is usually different for payers and employers. Then consider how we define value in oncology reflects on us as a society. Strategize how these different perspectives fit together to yield a value equation that considers outcomes, patient experience, cost, and time...and yet it is not enough. Each stakeholder brings their own perspective to the relative value of these variables, resulting in solutions that address some issues while creating new ones. Hear about the role you can play in defining oncology value going forward, and in so doing, help drive to a better—and more equitable—cancer care delivery system.

9:15 – 10:15 AM EST
AACC’s 2021-2022 President’s Panel: Making the Business Case for Comprehensive Cancer Care Services

Krista Nelson, MSW, LCSW, OSW-C, FAOSW, Program Manager of Quality & Research, Cancer Support Services and Compassion, Providence Health & Services
Jennifer Bires, MSW, LCSW, OSW-C, Executive Director, Life with Cancer and Patient Experience, Inova Schar Cancer Institute
Al B. Benson III, MD, FACP, FASCO, Professor of Medicine, Robert H. Lurie Comprehensive Cancer Center at Northwestern Medicine
Courtney Bitz, MSW, LCSW, OSW-C, Director of Clinical Social Work and Spiritual Care, Department of Supportive Care Medicine, City of Hope
Olalekan Ajayi, PharmD, MBA, Chief Operating Officer, Highlands Oncology Group, PA

The delivery of high-impact comprehensive cancer care services requires innovative care models with demonstrable return on investment (ROI). To help support this effort, hear an update about the ACCC Comprehensive Cancer Care Services Survey, designed to
help explain benchmarking for and barriers to comprehensive cancer care, including lack of sufficient reimbursement, staffing, and budget. Then learn about the development of two new ACCC tools, Making the Business Case for Hiring an Oncology Social Worker and Making the Business Case for Hiring an Oncology Pharmacist, including how to leverage these tools to demonstrate ROI to hospital and practice leadership to help grow and support your cancer care team, expand your service line offerings, and improve the care you provide to patients with cancer and their families.

10:15 – 10:45 AM EST  
Networking Break

10:45 – 11:45 AM EST  
Precision Medicine vs. Value-Based Payment  

Alexis Finkelberg Bortniker, JD, Partner, Foley & Lardner  
Ira Klein, MD, MBA, FACP, Vice President, Medical Affairs & Payer Relations, Tempus Labs  
Deirdre Saulet, PhD, Expert Partner, Advisory Board Company  
James Hamrick, MD, MPH, Vice President, Clinical Oncology, Flatiron Health  
@HJamesHamrick

11:50 – 12:50 PM EST  
What's Trending in Pharmacy and Infusion Services  

Steve D'Amato, BScPharm, Founding Partner, Scientia Pharmacy Advisors, LLC  
John Hennessey, MBA, CMPE, Senior Vice President, Strategist, Valuate Health Consultancy  
@Jehennesy3  
Deirdre Saulet, PhD, Expert Partner, Advisory Board Company  
Bhavesh Shah, RPh, BCOP, Associate Chief Pharmacy Officer, Specialty and Hematology Oncology Pharmacy, Boston Medical Center  
@Bhavesh13705158

1:00 – 2:00 PM EST  
Closing Luncheon Session: Cancer Care is Different: The Oncology Patients’ Bill of Rights  

Joe Alvarnas, MD, Vice President of Government Affairs; Chief Clinical Advisor, AccessHope; Professor, Department of Hematology & Hematopoietic Cell Transplant, City of Hope National Medical Center  
@Alvarnasjoseph  
Alexis Finkelberg Bortniker, JD, Partner, Foley & Lardner

Providing healthcare for cancer is different than for any other disease. Cancer is now recognized not as one condition, but as multiple conditions. With genomic sequencing technology, cancer may soon be viewed as potentially hundreds of conditions. In 2021, the California State Assembly unanimously passed the Cancer Patients Bill—the first
of its kind in the nation—which calls for six rights that every cancer patient in California should have. Access and equity are key components across these six rights, and this session will focus on grounded approaches to moving access and equity forward in meaningful ways. Creative solutioning includes establishing community-academic collaborations that are easily scaled and that ensure patients receive treatment in the communities where they live and developing care-focused strategies in partnership with employers. Hear patient stories, join the discussion, and return with ideas on how your cancer program or practice can work with your state legislators to improve the care of patients with cancer in your community.

Last updated 03.1.2022 | Agenda subject to change